HerediGENE is a test that fully analyzes a panel of 52 genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
prime DX is a cancer molecular test that incorporates a 1021 tumor-related multi-gene panel associated with the patient's response on targeted therapies, PARP inhibitors and chemotherapy.
The prime DX new technology for tumor molecular profiling is compatible with both FFPE and PLASMA.
Personalized pharmacotherapy based on human DNA.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze the genes associated with inherited cardiovascular disease.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders.
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
The MyThrombogene gene test examines the presence of specific mutations in genes that have been shown to be associated with thrombophilia and significantly increase the risk of thrombosis.
The MyWes gene test analyzes more than 20,000 genes associated with inherited diseases, helping the doctor diagnose diseases with unclear phenotypes and antenatal care.
Molecular Detection of Residual Disease
RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability.
The exam has been removed and replaced by the prime DX assay
A pioneering test for the early detection of pancreatic cancer
Genekor is a Molecular Biology Laboratory, focused in Oncology, Cardiology, Neurology and Pharmacogenetics. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector. A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in Oncology, Cardiology, Neurology and Pharmacogenetics.
See Genekor' s publications and posters.
Through a two-year program, patients with suspected symptoms from Greece, Romania, Poland, the Czech Republic, Hungary, Ukraine and Israel gain free access to genetic testing with the advanced NGS (New Generation Sequencing) method, which ensures fast and reliable diagnosis of rare diseases.
More than 7,000 rare diseases that affect more than 300,000,000 people around the world have been identified in recent years. This fact causes the need to use particularly innovative diagnostic tools, in order to achieve the absolute person-centered approach to the patient and to follow the correct treatment through precision medicine.
In this context, Sanofi Greece presented an innovative initiative aimed at the early diagnosis of rare diseases, thus reducing the often long and soul-destroying journey of the sufferers.
The samples from all the above countries will be analyzed in Genekor’s specialized molecular analysis laboratories in Greece, making it a center of patient access to medical innovation for the region of South-Eastern Europe, in the field of Rare Diseases.
30.11.2022
